MedTrace Logo

A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

NCT04935762 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-07-03

No results posted yet for this study

Summary

This is a Phase II, randomized, placebo-controlled, double-blind, crossover study to evaluate the effect of multiple oral doses of CST-103 in the presence of CST-107 on Freezing of Gait (FOG) symptoms in subjects with Parkinson's Disease (PD).

Conditions

  • Freezing of Gait Symptoms in Parkinson's Disease

Interventions

DRUG

CST-103, CST-107, matching placebo

CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules

Sponsors & Collaborators

  • CuraSen Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · CuraSen Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04935762 on ClinicalTrials.gov